Author Archives: Zyp Czyk

About Zyp Czyk

Until I was disabled by the progressive pain and fatigue from Ehlers-Danlos Syndrome and Fibromyalgia, I was a high tech IT maven at Apple and Yahoo. I live in a rustic cabin in the redwood forests of the Santa Cruz Mountains just up the hill from Silicon Valley with my wonderfully supportive husband and two 4-legged kids. I use my remaining energy to run an informational blog about "Living with Chronic Pain from EDS & Fibromyalgia". I publish daily updates with selected excerpts of news, research, treatments, tips, support, and personal stories along with my own notes.

“Bad Energy” is Core Problem in Fibromyalgia and CFS

Study Suggests “Bad Energy” is Core Problem in Fibromyalgia and Chronic Fatigue Syndrome (ME/CFS) – Health Rising – by Cort Johnson | May 31, 2017

Lactate has become a big deal in both chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM).  A by-product of anaerobic energy metabolism, lactate ordinarily gets pumped out of our cells in large amounts during exertion.

The lactate findings suggest that the energy needs of ME/CFS/FM patients are largely being addressed by glycolysis or anaerobic energy production.

Anaerobic energy production plays an important role in energy production, but when aerobic energy production is not available and it becomes the major source of energy it produces metabolites that produce the burning muscles, fatigue and other symptoms we associate with over-exercise.  Continue reading

Surrogate end points in clinical research: Hazardous

Surrogate end points in clinical research: hazardous to your health. – PubMed – NCBI – Obstet Gynecol. 2005 May

Surrogate end points in clinical research pose real danger.

A surrogate end point is an outcome measure, commonly a laboratory test, that substitutes for a clinical event of true importance.

Resistance to activated protein C, for example, has been used as a surrogate for venous thrombosis in women using oral contraceptives.

Other examples of inappropriate surrogate end points in contraception include the  Continue reading

Better State Guidelines for Use of Opioid Analgesics

Guidelines for the Chronic Use of Opioid Analgesics from State Medical Boards Opioid Guidelines As Adopted April 2017_FINAL.pdf

Adopted as policy by the Federation of State Medical Boards April 2017

INTRODUCTION

In April 2015, the Federation of State Medical Boards (FSMB) Chair, J. Daniel Gifford, MD, FACP, appointed the Workgroup on FSMB’s Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain to review the current science for treating chronic pain with opioid analgesics and to revise the Model Policy as appropriate.

In updating its existing policy, the FSMB sought input from a diverse group of medical and policy stakeholders that ranged from experts in pain medicine and addiction to government officials and other thought leaders. 

This what the CDC should have done as well, but did not.  Continue reading

Response to FDA’s Request to Pull Opana Off Market

AIPM’s Response to FDA’s Request to Pull Opana ER Off Market – Academy of Integrative Pain Management Blog

On Thursday, June 8, the U.S. Food and Drug Administration “requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market,” the FDA said in a statement.

Apparently Opana ER, an extended release form of the opioid drug oxymorphone, was being crushed up and injected by people seeking to abuse it.

“After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.”   Continue reading

CRISPR gene editing can cause unintended mutations

CRISPR gene editing can cause hundreds of unintended mutations | EurekAlert! Science News – May 29, 2017

This is an example of how new drugs developed with the latest new technologies can lead to dangerous unintended side-effects that only become apparent later after many subjects have been “treated”.

When a new technology, like CRISPR gene editing, is used we cannot use past experience to assume anything and cannot predict results precisely because we’re doing something categorically different from before.

As CRISPR-Cas9 starts to move into clinical trials, a new study published in Nature Methods has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome Continue reading

THC Potentiates Analgesic Effects of Opioids

Persistent Potentiation of the Analgesic Effects of Opioids by Delta-9Tetrahydrocannabinol (THC) in Nonhuman Primates – Apr 2017

Improving the analgesic effectiveness of opioids while also reducing the adverse effects is a major goal of pain research.

One approach to this problem has been to combine drugs such as cannabinoids with opioids to determine if this might reduce the dose of opioid required to produce analgesia.

In this experiment, male nonhuman primates (rhesus macaques) were administered a range of doses of THC in combination with cumulative doses of heroin to determine if the combinations produced greater analgesia than that observed with heroin alone.

Briefly, the animals were secured in standard primate ch  airs, tails were shaved, and dipped in a mixed order in three different water temperatures (40 °, 50 °, and 55 °C) until the animal rapidly withdrew his tail, or 20 seconds elapsed. Continue reading

Unexpected mechanism behind chronic nerve pain

Unexpected mechanism behind chronic nerve pain | News | News | Karolinska Institutet

It has long been assumed that chronic nerve pain is caused by hypersensitivity in the neurons that transmit pain.

Researchers at Karolinska Institutet in Sweden now show that another kind of neuron that normally allows us to feel pleasant touch sensation, can switch function and instead signal pain after nerve damage.

The results, which are presented in the journal Science, can eventually lead to more effective pain treatments.  Continue reading

Ketamine for Pain Management, Treatment of Depression

Ketamine for Pain Management, Treatment of DepressionLinda Peckel – May 30, 2017

Ketamine may alleviate depression, pain, and side effects associated with opioid treatment, and may thus represent an attractive adjunct therapy for pain management, according to a novel population analysis recently published in Scientific Reports.

Nearly half of all patients with depression taking conventional antidepressants discontinue their treatment prematurely.

 Researchers have sought alternatives to standard antidepressants, for which therapeutic effects are delayed by 2 to 10 weeks.   Continue reading

Cells carry ‘memory’ of injury

Cells carry ‘memory’ of injury, which could reveal why chronic pain persists | EurekAlert! Science News – May-2016

A new study from King’s College London offers clues as to why chronic pain can persist, even when the injury that caused it has gone.

Although still in its infancy, this research could explain how small and seemingly innocuous injuries leave molecular ‘footprints’ which add up to more lasting damage, and ultimately chronic pain.

While chronic pain can have many different causes, the outcome is often the same: an overly sensitive nervous system which responds much more than it normally would Continue reading

Call lawyers Morgan & Morgan and tell your story

» call MORGAN & MORGAN ..tell your story… refer to chronic pain patient class action PHARMACIST STEVE June 19, 2017 by Steve Ariens

 Chronic Pain Patients – Call Now
Morgan & Morgan Lawyers
888-670-2630

Ask for the medical malpractice department.
Refer to chronic pain patient class action and tell your story. 
Continue reading